Nasdaq:US$31.51 (-1.39) | HKEX:HK$54.80 (-0.35) | AIM:£5.11 (+0.04)
Search Result
Previous Article   |   Next Article
Scientific Publications | 4 Jun 2021

ASCO 2021: An Open-Label Phase 1b/2 Study of Surufatinib in Combination with Tislelizumab  in Patients with Advanced Solid Tumors